A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Status:	Completed
Conditions:	Schizophrenia
Therapuetic Areas:	Psychiatry / Psychology
Healthy:	No
Age Range:	18 - 65
Updated:	8/3/2016
Start Date:	February 2011
End Date:	September 2012

A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia

This randomized, double-blind, placebo- and active-controlled, parallel group study will
evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute
exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg
or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients,
with a 4-week follow-up period.

Inclusion Criteria:

- Adult patients, 18-65 years of age

- Diagnosis of schizophrenia (Diagnostic and Statistical Manual of Mental Disorders DSM
IV-TR)

- Acute exacerbation which began within the prior 8 weeks

- Female patients must be surgically sterile or post-menopausal, or agree to use
effective contraception for the duration of the study

Exclusion Criteria:

- Current psychiatric diagnosis other than schizophrenia

- Alcohol or substance dependence within 3 months or abuse within 1 month (except for
nicotine)

- Electro-convulsive therapy (ECT) within the prior 6 months

- Previous treatment with RO4917838 or another GLYT inhibitor

- Current treatment with olanzapine, or previous treatment with intolerability or lack
of response

- Treatment with long-acting injectable antipsychotic within 2 dosing intervals

- Treatment with > 2 antipsychotics within 3 months

- History of neuroleptic malignant syndrome

- Have treatment-resistant schizophrenia as judged by treating physician or have failed
two trials according to criteria in protocol

We found this trial at

sites

Clinical Trial Facility in Arad

Arad, 31002

from

Arad,